Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.